Researchers at the University of Maryland School of Medicine found that patients treated in an intensive care unit for COVID-19 had a significantly lower risk of complications and death when taking low-dose aspirin compared to patients who did not take ASA. The research results were recently presented in the journal “Anesthesia & Analgesia”.
Severely ill COVID-19 patients in hospital had a lower risk of dying from the coronavirus SARS-CoV-2 if they received low-dose acetylsalicylic acid (ASA) daily. The risk of complications also decreased. These are the results of a US study.
According to the study results, hospitalized COVID-19 patients who received daily low-dose ASA to protect against cardiovascular disease had a significantly lower risk of complications and death compared to patients who did not receive aspirin. Participants in the aspirin group were transferred to intensive care units less frequently, required mechanical ventilation less frequently and were more likely to survive the infection.
The research team speaks of a “cautious optimism” for a low-cost and readily available drug with a well known safety profile that could prevent serious complications with COVID-19. “This is a critical finding that must be confirmed by a randomized clinical trial,” emphasizes study leader Dr. Jonathan Chow. If the observations are confirmed, the first widely available over-the-counter drug that reduces COVID-19 mortality would be available.
ASS improved COVID-19 prognosis in critically ill patients
Chow’s team analyzed the medical records of 412 COVID-19 patients with an average age of 55 years who were treated at the University of Maryland Medical Center in Baltimore and three other hospitals over the past months. About a quarter of the participants took low-dose ASA to treat cardiovascular disease. The average daily intake of ASA was 81 milligrams.
According to the research results, taking aspirin was associated with a 44 percent lower risk of being connected to a ventilator. The risk of being admitted to an intensive care unit was reduced by 43 percent. The risk of dying from COVID-19 was reduced by 47 percent overall as a result of ASA intake. In addition, serious complications such as internal bleeding were less frequent.
During COVID-19 infection, the risk of dangerous blood clots forming in the heart, lungs or blood vessels is increased. In severe cases, such clots can trigger heart attacks, strokes or multiple organ failure. Such events often lead to death during COVID-19 disease. “We believe that the blood-thinning effect of aspirin brings benefits to COVID-19 patients by preventing the formation of microcoagulants,” said study co-author Professor Michael A. Mazzeffi.
Aspirin appears to reduce COVID-19 mortality risk
“The results seem plausible due to the mode of action of ASA,” writes the German Medical Journal (Deutsches Ärzteblatt) regarding the study results. However, a basis for a therapeutic application is not yet available. Read also: Corona: These blood groups influence the risk of infection. (vb)
The working group recommends that persons suffering from COVID-19 should consider taking ASA in consultation with their treating physician. In people with an increased risk of bleeding or chronic kidney disease, as well as when taking certain other medications (such as steroids or blood thinners), aspirin intake may not be recommended.
WashingtonNewsday Health and Wellness.